Sandoz, the Swiss generics and biosimilar drug developer, is to invest $90 million at its site in Ljubljana, Slovenia to produce biosimilar medicines, which are off-patent drugs similar in mechanism of action to their reference biologic drugs. The new technical center is expected to drive biosimilar development, leading to the creation of about 200 new full-time jobs. The project is anticipated to complete by 2026.
